# 111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer

> **NCT01445054** · EARLY_PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Colon Cancer

## Interventions

- **DRUG:** 111Indium CHX-A

## Key facts

- **NCT ID:** NCT01445054
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03-01
- **Primary completion:** 2014-08-20
- **Final completion:** 2014-08-20
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445054, "111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01445054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*